BTN3A2

BTN3A2 is a butyrophilin family member that functions as a direct Vγ9Vδ2 T cell receptor ligand within a trimeric BTN3A1–BTN3A2–BTN2A1 complex; upon phosphoantigen-driven activation, the BTN3A2–BTN2A1 ectodomain interaction dissociates, enabling BTN3A2 to engage the Vδ2 chain via a pliers-like gripping mechanism [PMID:bio_10.1101_2024.10.02.616253]. Beyond immune recognition, BTN3A2 interacts with the SARS-CoV-2 Spike receptor-binding domain and reduces ACE2 levels, protecting against viral infection in vitro and in transgenic mice (PMID:39142074). BTN3A2 also modulates excitatory synaptic transmission through interaction with neurexins (PMID:31133542), promotes hypoxia-induced ferroptosis by downregulating MFGE8 to inhibit angiogenesis (PMID:40147528), and drives glioma temozolomide resistance via a HIF-1α–activated AKT/SP1/RAD51 DNA repair axis (PMID:41965757).

1. 2017 Medium

   Establishing that BTN3A2 has a functional role in epithelial cancer biology: CRISPR knockout demonstrated that BTN3A2 loss inhibits gastric cancer cell proliferation, migration, and invasion, while a regulatory haplotype modulates its expression through enhancer activity.

   Evidence CRISPR/Cas9 knockout in gastric cancer cell lines with proliferation/migration/invasion assays and reporter/enhancer assay

   PMID:28246015

   Open questions at the time

   • Mechanism by which BTN3A2 promotes proliferation and invasion not defined
   • No signaling pathway downstream of BTN3A2 identified in this cancer context
   • Single study without independent replication
2. 2019 Medium

   Revealing a neuronal function: BTN3A2 suppresses excitatory synaptic activity onto hippocampal CA1 pyramidal neurons through interaction with presynaptic neurexins, establishing a trans-synaptic adhesion role.

   Evidence Electrophysiology in rat hippocampal slices with BTN3A2 overexpression; cell surface binding assay for neurexin interaction

   PMID:31133542

   Open questions at the time

   • Specific neurexin isoform(s) mediating the interaction not mapped
   • Mechanism connecting neurexin binding to synaptic suppression not resolved
   • No loss-of-function validation in neurons
3. 2024 High

   Demonstrating antiviral function: BTN3A2 directly binds SARS-CoV-2 Spike RBD and ACE2, competitively inhibiting viral attachment and reducing ACE2 surface levels, protecting against infection both in vitro and in vivo.

   Evidence Immunoprecipitation, biolayer interferometry, competition ELISA, BTN3A2 gene-edited cells, and transgenic mice infected with live SARS-CoV-2

   PMID:39142074

   Open questions at the time

   • Structural basis of the BTN3A2–RBD and BTN3A2–ACE2 interactions not determined
   • Whether BTN3A2 restricts other coronaviruses is unknown
   • Mechanism of ACE2 downregulation not fully elucidated
4. 2024 High

   Resolving the structural mechanism of phosphoantigen-dependent γδ T cell activation: cryo-EM showed BTN3A2 forms a resting-state complex with BTN3A1 and BTN2A1 where BTN3A2 ectodomains associate with BTN2A1; phosphoantigen binding triggers dissociation, allowing BTN3A2 to directly engage the Vδ2 TCR chain as a bona fide ligand.

   Evidence Cryo-EM structures of full-length BTN3A1–BTN3A2–BTN2A1 complex in resting and TCR-engaged states (preprint)

   PMID:bio_10.1101_2024.10.02.616253

   Open questions at the time

   • Preprint awaiting peer review
   • Kinetics of the conformational switch from resting to engaged state not measured
   • Relative contributions of BTN3A2 versus BTN2A1 ectodomains to TCR activation affinity not quantified
5. 2025 Medium

   Linking BTN3A2 to vascular biology: BTN3A2 interacts with MFGE8 and promotes hypoxia-induced ferroptosis in endothelial cells by downregulating MFGE8, inhibiting angiogenesis; knockdown in a rat preeclampsia model improved placental angiogenesis.

   Evidence Co-immunoprecipitation for BTN3A2–MFGE8; siRNA knockdown and overexpression in HUVECs under hypoxia; rat preeclampsia model

   PMID:40147528

   Open questions at the time

   • Mechanism by which BTN3A2 downregulates MFGE8 (degradation vs. transcriptional) not defined
   • Single study without independent confirmation of MFGE8 interaction
   • Ferroptosis pathway components directly engaged by BTN3A2 not identified
6. 2026 Medium

   Defining a chemoresistance mechanism in glioma: HIF-1α directly activates BTN3A2 transcription under hypoxia, and BTN3A2 enhances DNA damage repair through the AKT/SP1/RAD51 axis, conferring temozolomide resistance.

   Evidence CUT&Tag, promoter luciferase assay, RNA-seq, lentiviral BTN3A2 knockdown with in vitro and in vivo functional assays

   PMID:41965757

   Open questions at the time

   • Direct physical interaction between BTN3A2 and AKT pathway components not demonstrated
   • Whether AKT/SP1/RAD51 axis activation is specific to glioma or generalizable is unknown
   • Single study; independent replication needed

• A unifying mechanism explaining how a single transmembrane butyrophilin mediates such diverse functions — immune TCR engagement, synaptic modulation, antiviral defense, ferroptosis regulation, and DNA repair — remains unresolved, particularly whether these reflect context-dependent interactions of the same ectodomain or distinct signaling through the intracellular domain.
• No structure–function mapping linking specific BTN3A2 domains to non-immune functions
• Relative physiological importance of immune versus non-immune roles in vivo unknown
• No interactome study comprehensively cataloguing BTN3A2 binding partners across tissues